Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CRMD's Cash to Debt is ranked higher than
82% of the 963 Companies
in the Global Biotechnology industry.

( Industry Median: 83.29 vs. CRMD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
CRMD' s Cash to Debt Range Over the Past 10 Years
Min: 0.11  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.83
CRMD's Equity to Asset is ranked higher than
69% of the 711 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CRMD: 0.83 )
Ranked among companies with meaningful Equity to Asset only.
CRMD' s Equity to Asset Range Over the Past 10 Years
Min: -1.36  Med: 0.82 Max: 0.95
Current: 0.83
-1.36
0.95
F-Score: 3
Z-Score: 1.38
M-Score: -4.94
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -17779.20
CRMD's Operating margin (%) is ranked lower than
95% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -81.51 vs. CRMD: -17779.20 )
Ranked among companies with meaningful Operating margin (%) only.
CRMD' s Operating margin (%) Range Over the Past 10 Years
Min: -245750  Med: -7930.48 Max: -4710.05
Current: -17779.2
-245750
-4710.05
Net-margin (%) -17688.00
CRMD's Net-margin (%) is ranked lower than
95% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. CRMD: -17688.00 )
Ranked among companies with meaningful Net-margin (%) only.
CRMD' s Net-margin (%) Range Over the Past 10 Years
Min: -456650  Med: -10821.69 Max: -8660.95
Current: -17688
-456650
-8660.95
ROE (%) -72.36
CRMD's ROE (%) is ranked lower than
72% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: -32.93 vs. CRMD: -72.36 )
Ranked among companies with meaningful ROE (%) only.
CRMD' s ROE (%) Range Over the Past 10 Years
Min: -678.23  Med: -155.37 Max: -96.8
Current: -72.36
-678.23
-96.8
ROA (%) -65.00
CRMD's ROA (%) is ranked lower than
76% of the 967 Companies
in the Global Biotechnology industry.

( Industry Median: -29.03 vs. CRMD: -65.00 )
Ranked among companies with meaningful ROA (%) only.
CRMD' s ROA (%) Range Over the Past 10 Years
Min: -507.14  Med: -196.95 Max: -86.2
Current: -65
-507.14
-86.2
ROC (Joel Greenblatt) (%) -22152.30
CRMD's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 927 Companies
in the Global Biotechnology industry.

( Industry Median: -368.19 vs. CRMD: -22152.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRMD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -53119.48  Med: -37507.32 Max: -25220.83
Current: -22152.3
-53119.48
-25220.83
EBITDA Growth (3Y)(%) 30.30
CRMD's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CRMD: 30.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRMD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -66.6  Med: 0.85 Max: 30.3
Current: 30.3
-66.6
30.3
EPS Growth (3Y)(%) 24.60
CRMD's EPS Growth (3Y)(%) is ranked higher than
80% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. CRMD: 24.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRMD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.4  Med: 1.3 Max: 24.6
Current: 24.6
-68.4
24.6
» CRMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

CRMD Guru Trades in Q4 2015

Paul Singer 1,500,200 sh (unchged)
» More
Q1 2016

CRMD Guru Trades in Q1 2016

Paul Singer 1,500,200 sh (unchged)
» More
Q2 2016

CRMD Guru Trades in Q2 2016

Paul Singer 1,500,200 sh (unchged)
» More
Q3 2016

CRMD Guru Trades in Q3 2016

Paul Singer 1,500,200 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:CWBR, OTCPK:CNBX, NAS:CATB, NAS:CALA, OTCPK:NURPF, NAS:BUR, NAS:ALDX, NAS:ANTH, NAS:PPHM, NAS:LIFE, OTCPK:RCAR, NAS:AGLE, NAS:DRNA, NAS:AFMD, NAS:NEPT, NAS:ADMA, NAS:TCON, NAS:CAPR, NAS:SBPH, NAS:PIRS » details
Traded in other countries:19K.Germany,
Cormedix Inc is a development stage pharmaceutical and medical device company. It seeks to in-license, develop and commercialize therapeutic products for the treatment of cardiorenal and infectious diseases, including the dialysis and non-dialysis areas.

Cormedix Inc was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.

Ratios

vs
industry
vs
history
P/B 2.98
CRMD's P/B is ranked higher than
58% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: 3.57 vs. CRMD: 2.98 )
Ranked among companies with meaningful P/B only.
CRMD' s P/B Range Over the Past 10 Years
Min: 1.3  Med: 3.51 Max: 33.26
Current: 2.98
1.3
33.26
P/S 583.33
CRMD's P/S is ranked lower than
93% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 12.03 vs. CRMD: 583.33 )
Ranked among companies with meaningful P/S only.
CRMD' s P/S Range Over the Past 10 Years
Min: 151.11  Med: 475.72 Max: 2810
Current: 583.33
151.11
2810
EV-to-EBIT -1.99
CRMD's EV-to-EBIT is ranked lower than
99.99% of the 317 Companies
in the Global Biotechnology industry.

( Industry Median: 20.32 vs. CRMD: -1.99 )
Ranked among companies with meaningful EV-to-EBIT only.
CRMD' s EV-to-EBIT Range Over the Past 10 Years
Min: -22.6  Med: -2.3 Max: -0.2
Current: -1.99
-22.6
-0.2
EV-to-EBITDA -2.00
CRMD's EV-to-EBITDA is ranked lower than
99.99% of the 346 Companies
in the Global Biotechnology industry.

( Industry Median: 16.98 vs. CRMD: -2.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -22.6  Med: -2.3 Max: -0.2
Current: -2
-22.6
-0.2
Current Ratio 5.71
CRMD's Current Ratio is ranked higher than
59% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CRMD: 5.71 )
Ranked among companies with meaningful Current Ratio only.
CRMD' s Current Ratio Range Over the Past 10 Years
Min: 0.1  Med: 4.64 Max: 20.26
Current: 5.71
0.1
20.26
Quick Ratio 5.68
CRMD's Quick Ratio is ranked higher than
60% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. CRMD: 5.68 )
Ranked among companies with meaningful Quick Ratio only.
CRMD' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 4.53 Max: 19.89
Current: 5.68
0.1
19.89
Days Inventory 276.58
CRMD's Days Inventory is ranked lower than
81% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 129.09 vs. CRMD: 276.58 )
Ranked among companies with meaningful Days Inventory only.
CRMD' s Days Inventory Range Over the Past 10 Years
Min: 72.28  Med: 222.19 Max: 480.56
Current: 276.58
72.28
480.56
Days Sales Outstanding 64.24
CRMD's Days Sales Outstanding is ranked lower than
52% of the 595 Companies
in the Global Biotechnology industry.

( Industry Median: 63.02 vs. CRMD: 64.24 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 154.5  Med: 365 Max: 549.24
Current: 64.24
154.5
549.24
Days Payable 1.00
CRMD's Days Payable is ranked lower than
98% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 57.68 vs. CRMD: 1.00 )
Ranked among companies with meaningful Days Payable only.
CRMD' s Days Payable Range Over the Past 10 Years
Min: 730.82  Med: 1698.51 Max: 1955.44
Current: 1
730.82
1955.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -46.60
CRMD's 3-Year Average Share Buyback Ratio is ranked lower than
85% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -11.20 vs. CRMD: -46.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -137  Med: -35.95 Max: -13.3
Current: -46.6
-137
-13.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.30
CRMD's Price/Net Cash is ranked higher than
74% of the 875 Companies
in the Global Biotechnology industry.

( Industry Median: 6.19 vs. CRMD: 3.30 )
Ranked among companies with meaningful Price/Net Cash only.
CRMD' s Price/Net Cash Range Over the Past 10 Years
Min: 2.01  Med: 3.98 Max: 41
Current: 3.3
2.01
41
Price/Net Current Asset Value 2.97
CRMD's Price/Net Current Asset Value is ranked higher than
75% of the 1006 Companies
in the Global Biotechnology industry.

( Industry Median: 5.65 vs. CRMD: 2.97 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CRMD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.93  Med: 3.59 Max: 36.44
Current: 2.97
1.93
36.44
Price/Tangible Book 2.98
CRMD's Price/Tangible Book is ranked higher than
66% of the 1150 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CRMD: 2.98 )
Ranked among companies with meaningful Price/Tangible Book only.
CRMD' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.93  Med: 3.6 Max: 36.04
Current: 2.98
1.93
36.04
Price/Median PS Value 1.24
CRMD's Price/Median PS Value is ranked lower than
66% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CRMD: 1.24 )
Ranked among companies with meaningful Price/Median PS Value only.
CRMD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.42  Med: 0.8 Max: 5.34
Current: 1.24
0.42
5.34
Earnings Yield (Greenblatt) (%) -50.30
CRMD's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: -8.00 vs. CRMD: -50.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRMD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1325.05  Med: 0 Max: 0
Current: -50.3
-1325.05
0

More Statistics

Revenue (TTM) (Mil) $0.13
EPS (TTM) $ -0.58
Beta1.71
Short Percentage of Float10.98%
52-Week Range $1.15 - 4.54
Shares Outstanding (Mil)40.43

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 0 1 8 5
EPS ($) -0.61 -0.52 -0.43 -0.30
EPS w/o NRI ($) -0.61 -0.52 -0.43 -0.30
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for CRMD

Headlines

Articles On GuruFocus.com
Paul Singer's Latest Portfolio Increases and Reduction Mar 04 2015 
Weekly CFO Buys Highlight: CEP, JNS, CRMD, VAC, TICC Dec 26 2011 
Weekly CFO Buys Highlight: POL, ARAY, ZBB, CRMD, VRX Dec 19 2011 
CORMEDIX INC Reports Operating Results (10-Q) Nov 09 2010 

More From Other Websites
CORMEDIX INC. Financials Nov 17 2016
ETFs with exposure to CorMedix, Inc. : November 14, 2016 Nov 14 2016
CorMedix, Inc. :CRMD-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016 Nov 11 2016
CORMEDIX INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 10 2016
CorMedix Inc. Reports Third Quarter 2016 Financial Results and Provides Business Updates Nov 10 2016
CORMEDIX INC. Files SEC form 10-Q, Quarterly Report Nov 09 2016
CORMEDIX INC. Files SEC form 8-K, Other Events Nov 03 2016
CorMedix Inc. to Report Third Quarter 2016 Financial Results Nov 02 2016
ETF’s with exposure to CorMedix, Inc. : October 18, 2016 Oct 18 2016
CORMEDIX INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Oct 03 2016
CorMedix Inc. Appoints Khoso Baluch as Chief Executive Officer Oct 03 2016
ETF’s with exposure to CorMedix, Inc. : September 28, 2016 Sep 28 2016
CorMedix Inc. to Present at Multiple Investor and Industry Conferences Sep 20 2016
CORMEDIX INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 16 2016
CorMedix, Inc. Announces Signing of an Agreement with POETIC (Pediatric Oncology Experimental... Sep 15 2016
ETF’s with exposure to CorMedix, Inc. : September 8, 2016 Sep 08 2016
CorMedix Inc. to Present at 2016 Rodman & Renshaw 18th Annual Global Investment Conference Sep 06 2016
A Look at Billionaire Paul Singer’s Long-Term Investments Aug 16 2016
CorMedix Inc. Invited to Present at Two Upcoming Scientific Conferences Aug 16 2016
ETF’s with exposure to CorMedix, Inc. : August 12, 2016 Aug 12 2016
CorMedix (CRMD) Shows Strength: Stock Moves Up 24.8% Aug 12 2016
CorMedix, Inc. :CRMD-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016 Aug 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)